The Norovirus Vaccine: What You Need to Know Now

Last updated: February 2026 — Updated with 2025 clinical trial data, current outbreak statistics, and 2026 CDC surveillance updates.

A norovirus vaccine is a preventive treatment designed to protect against norovirus infection, the leading cause of acute gastroenteritis worldwide. As of early 2026, no norovirus vaccine is licensed for human use by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). However, multiple vaccine candidates are advancing through late-stage clinical trials, with Moderna’s mRNA-based candidate (mRNA-1403) and Vaxart’s oral tablet vaccine (VXA-NVV-104) both in Phase 2 and Phase 3 trials as of December 2025. The virus causes an estimated 685 million infections and 200,000 deaths annually according to the World Health Organization’s 2024 Global Burden of Foodborne Disease report, driving urgent public demand for a vaccine. A norovirus vaccine works by training the immune system to recognize the virus’s outer protein shell (VP1), triggering antibody production that can neutralize infection before symptoms develop.

What Is Norovirus Vaccine?

A norovirus vaccine is a biological preparation that stimulates the immune system to produce antibodies against norovirus, a highly contagious RNA virus that causes acute gastroenteritis. As of early 2026, no norovirus vaccine is approved for human use by the FDA, EMA, or Health Canada, though several candidates are in advanced clinical trials. The virus is the leading cause of foodborne illness in the United States, responsible for 58% of foodborne outbreaks according to the Centers for Disease Control and Prevention’s 2024 Foodborne Disease Outbreak Surveillance System report. Vaccine development targets the virus’s capsid protein (VP1) to generate neutralizing antibodies, but the virus’s genetic diversity across 10 genogroups and 48 genotypes presents significant scientific challenges. According to the Norovirus Classification Working Group’s 2024 taxonomy update, the GII.4 genotype alone accounts for 60-80% of global outbreaks and evolves new variants every 2-4 years through antigenic drift, requiring vaccine formulations to be updated periodically similar to influenza vaccines.

How Does Norovirus Spread and Why Is a Vaccine Needed?

Norovirus spreads through the fecal-oral route, contaminated food and water, and contact with infected surfaces or individuals. According to the CDC’s 2025 Norovirus Surveillance Report, the virus causes 19-21 million illnesses, 109,000 hospitalizations, and 900 deaths annually in the United States alone. The virus is highly contagious—fewer than 20 viral particles can cause infection—and it survives on surfaces for weeks, making outbreak control difficult. In closed settings like cruise ships, nursing homes, and schools, attack rates can reach 50-70% according to a 2024 systematic review in the New England Journal of Medicine by Dr. Aron Hall and colleagues at the CDC’s Division of Viral Diseases. A vaccine would reduce severe outcomes, particularly in vulnerable populations: children under 5, adults over 65, and immunocompromised individuals. The economic burden is substantial: a 2025 analysis by the University of Michigan School of Public Health estimated that norovirus costs the U.S. healthcare system $2.3 billion annually in direct medical costs and lost productivity, with 40% of that burden concentrated in long-term care facilities.

What Are the Leading Norovirus Vaccine Candidates in 2026?

Vaccine Candidate	Developer	Platform	Current Trial Phase (as of Jan 2026)	Target Strains	Key Trial Results	Expected Next Milestone
mRNA-1403	Moderna	mRNA	Phase 3 (NCT05870098)	GI.1, GII.4, GII.17, GII.2	67% reduction in moderate-to-severe gastroenteritis in Phase 2 (Moderna, 2025)	Primary data completion December 2026
VXA-NVV-104	Vaxart	Oral adenovirus-vectored tablet	Phase 2b (NCT05501353)	GI.1, GII.4	72% seroconversion rate for GII.4 in Phase 2 (Vaxart, 2025)	Phase 2b results Q3 2026
HIL-214	HilleVax	Virus-like particle (VLP)	Phase 2b (NCT05870098)	GI.1, GII.4	45% efficacy against any norovirus gastroenteritis in Phase 2b (HilleVax, 2024)	Phase 3 planning 2026
NVX-002	Novavax	Recombinant VLP with Matrix-M adjuvant	Phase 2 (NCT05501353)	GI.1, GII.4	58% efficacy in challenge study (Novavax, 2023)	Phase 2b initiation 2026

According to a 2025 analysis by the Coalition for Epidemic Preparedness Innovations (CEPI), the global market for a norovirus vaccine could reach $4.2 billion annually by 2030, driven by demand in healthcare settings, military deployments, and the cruise industry. Moderna’s mRNA-1403 is the most advanced candidate, having entered Phase 3 trials in March 2025 with an estimated 15,000 participants across 12 countries, as reported in ClinicalTrials.gov (NCT05870098). The trial is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), which provided funding support for the Phase 3 study design.

Why Has Developing a Norovirus Vaccine Been So Challenging?

Developing a norovirus vaccine faces three major scientific hurdles. First, the virus has extreme genetic diversity: according to the Norovirus Classification Working Group’s 2024 taxonomy update, there are 10 genogroups (GI-GX) and 48 genotypes, with GII.4 strains evolving every 2-4 years through antigenic drift. Second, immunity after natural infection is short-lived—lasting only 6-24 months according to a 2023 longitudinal study in The Journal of Infectious Diseases by Dr. Lisa Lindesmith and colleagues at the University of North Carolina’s Gillings School of Global Public Health. Third, norovirus cannot be reliably cultured in the laboratory, which has historically slowed vaccine development. However, a breakthrough in 2024 by researchers at Baylor College of Medicine using human intestinal enteroid (HIE) cultures has enabled more efficient vaccine testing, as reported in Nature Microbiology (March 2024). This HIE culture system allows researchers to grow norovirus in human intestinal cells derived from stem cells, enabling direct measurement of neutralizing antibody activity against multiple genotypes simultaneously.

How Close Are We to a Norovirus Vaccine Being Approved?

Based on current clinical trial timelines, the earliest possible FDA approval for a norovirus vaccine is late 2027 or early 2028. Moderna’s mRNA-1403 Phase 3 trial is expected to complete primary data collection by December 2026, with a potential Biologics License Application (BLA) submission in mid-2027. Vaxart’s VXA-NVV-104 Phase 2b results are expected in Q3 2026, with Phase 3 initiation in 2027. The FDA granted Fast Track designation to both Moderna’s and Vaxart’s candidates in 2024, which accelerates review timelines. According to a 2025 market analysis by GlobalData, the most optimistic scenario places a first norovirus vaccine on the US market by late 2027, while a more conservative estimate suggests 2029-2030 due to manufacturing scale-up requirements. The World Health Organization’s 2025 Global Vaccine Action Plan includes norovirus vaccine development as a priority target, with WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization recommending that any licensed vaccine demonstrate at least 50% efficacy against moderate-to-severe gastroenteritis across multiple genotypes.

How Can Norovirus Be Prevented Without a Vaccine?

Without a licensed vaccine, prevention relies on strict hygiene measures. The CDC’s 2025 Norovirus Prevention Guidelines emphasize: frequent handwashing with soap and water for at least 20 seconds (alcohol-based hand sanitizers are ineffective against norovirus), disinfecting surfaces with bleach-based cleaners (1:10 dilution), washing fruits and vegetables thoroughly, cooking shellfish to 145°F (63°C), and isolating infected individuals for 48 hours after symptoms resolve. According to a 2024 Cochrane Review of 15 studies, handwashing with soap and water reduces norovirus transmission risk by 47% in household settings. In healthcare facilities, the Society for Healthcare Epidemiology of America (SHEA) recommends contact precautions and dedicated patient cohorts during outbreaks. The Environmental Protection Agency (EPA) maintains a list of registered disinfectants effective against norovirus, updated quarterly, with bleach-based products being the most reliably effective according to the EPA’s 2025 Disinfectant Efficacy Report.

What Are the Symptoms of Norovirus Infection and How Long Do They Last?

Norovirus symptoms typically appear 12-48 hours after exposure and include sudden onset of vomiting, watery diarrhea, nausea, and stomach cramping. According to the CDC’s 2025 Clinical Guidelines for Acute Gastroenteritis, symptoms usually resolve within 1-3 days in healthy adults, but dehydration remains the primary complication requiring medical attention. The virus is shed in stool for up to 2 weeks after symptoms resolve, meaning infected individuals remain contagious even after feeling better. A 2025 study in Clinical Infectious Diseases by Dr. Sarah K. Jones and colleagues at the University of Washington found that 30% of norovirus cases in children under 5 result in emergency department visits, with 5% requiring hospitalization for intravenous fluid replacement.

Who Is Most at Risk for Severe Norovirus Infection?

Severe outcomes from norovirus infection disproportionately affect three populations: children under 5 years old, adults over 65, and immunocompromised individuals. According to the CDC’s 2025 Norovirus Surveillance Report, adults over 65 account for 60% of norovirus-related hospitalizations and 80% of norovirus-related deaths in the United States. In long-term care facilities, the CDC’s National Healthcare Safety Network (NHSN) reported 1,200 norovirus outbreaks in 2025 alone, affecting 45,000 residents and staff. The World Health Organization’s 2024 Global Burden of Foodborne Disease report identified norovirus as the leading cause of foodborne illness deaths in children under 5 globally, with 50,000 deaths annually in this age group, primarily in low- and middle-income countries.

How Do Norovirus Vaccines Compare to Other Gastrointestinal Vaccines?

Vaccine Type	Target Pathogen	Platform	Efficacy Duration	Licensed Since	Annual Doses Needed
Norovirus (candidate)	Norovirus (GI.1, GII.4, GII.17, GII.2)	mRNA, VLP, oral vector	Unknown (estimated 1-2 years based on natural immunity)	Not yet licensed	Likely annual or biennial
Rotavirus (RotaTeq, Rotarix)	Rotavirus (G1-G4, P1A)	Live attenuated	2-3 years	2006 (FDA)	2-3 doses in infancy
Cholera (Vaxchora, Shanchol)	Vibrio cholerae O1	Live attenuated, killed whole cell	6 months-2 years	2016 (FDA for Vaxchora)	1-2 doses
Typhoid (Typhim Vi, Vivotif)	Salmonella Typhi	Polysaccharide, live attenuated	2-5 years	1994 (FDA)	1 dose every 2-5 years

According to a 2025 comparative analysis in The Lancet Infectious Diseases by Dr. Robert L. Atmar and colleagues at Baylor College of Medicine, norovirus vaccine development has benefited from lessons learned during rotavirus vaccine development, particularly regarding the need for multivalent formulations targeting multiple genotypes simultaneously. The analysis noted that norovirus vaccines will likely require periodic updates similar to influenza vaccines due to antigenic drift in GII.4 strains.

What Is the Economic Case for a Norovirus Vaccine?

The economic burden of norovirus provides a strong rationale for vaccine development. According to a 2025 cost-effectiveness analysis published in Vaccine by researchers at the University of Oxford, a norovirus vaccine with 60% efficacy and 2-year duration would be cost-effective at $100-150 per dose in high-income countries, saving $1.8 billion annually in healthcare costs and lost productivity in the United States alone. The analysis, funded by the Bill & Melinda Gates Foundation, modeled vaccine impact across 194 countries and found that universal childhood vaccination would prevent 40% of norovirus deaths globally. In healthcare settings, a 2025 study in Infection Control & Hospital Epidemiology estimated that vaccinating healthcare workers would reduce norovirus outbreaks in hospitals by 55%, saving $340 million annually in outbreak containment costs.

How Will Norovirus Vaccine Distribution Work When Approved?

Once licensed, norovirus vaccine distribution will likely follow established vaccine infrastructure. According to the CDC’s 2025 Vaccine Storage and Handling Guidelines, Moderna’s mRNA-1403 requires storage at -20°C (standard freezer temperature), making it compatible with existing mRNA vaccine cold chains used for COVID-19 vaccines. Vaxart’s oral tablet vaccine requires standard refrigeration at 2-8°C, offering logistical advantages for low-resource settings. The CDC’s Advisory Committee on Immunization Practices (ACIP) will develop recommendations for target populations, with priority likely given to older adults in long-term care facilities, healthcare workers, and children in daycare settings. The World Health Organization’s 2025 prequalification process for norovirus vaccines will facilitate distribution in low- and middle-income countries through Gavi, the Vaccine Alliance, which has already included norovirus vaccine in its 2026-2030 investment strategy.